Methods of diagnosing increased risk of developing mrsa
AssigneeWilliam Beaumont Hospital
InventorMatthew Sims
Life of this patent
Estimating the term…
Abstract
A method for diagnosing increased risk of developing Methicillin-resistant Staphylococcus aureus (MRSA) hospital-acquired (HA-MRSA) or community-acquired MRSA (CA-MRSA) which includes obtaining a biological sample from a subject, detecting in the sample a single nucleotide polymorphism (SNP) in the FAM129B gene at position 17 of SEQ ID NO 1, and comparing the nucleotide at position 17 of SEQ ID NO. 1 in the sample with the nucleotide at position 17 in SEQ ID NO. 1, wherein an adenine at position 17 of SEQ ID NO. 1 in the sample indicates an increased risk of developing MRSA or CA-MRSA in the subject.
Claims21
A method of predicting or assessing the level of risk of a subject developing a Methicillin-resistant S. aureus (MRSA) infection comprising:
- obtaining a biological sample from the subject, wherein said biological sample includes at least one oligonucleotide occupying a locus corresponding to position 17 of SEQ ID. NO 1;
- detecting the identity of at least one oligonucleotide occupying the locus corresponding to position 17 of SEQ ID. NO 1;
- determining whether at least one oligonucleotide occupying the locus corresponding to position 17 of SEQ ID. NO 1 is an adenine or a cytosine;
- and
- predicting and assessing the level of risk of the subject developing a MRSA, wherein an adenine occupying the locus corresponding to position 17 of SEQ ID. NO 1 indicates that the subject has a high risk of developing a MRSA infection and a cytosine occupying the locus corresponding to position 17 of SEQ ID. NO 1, indicates that the subject has a low risk of developing a MRSA infection.
One or more primers or probes to be used to amplify or detect at least one or more nucleotides from a biological sample, which one or more nucleotides occupy a locus corresponding to position 17 of SEQ. ID. NO. 1.
A method of monitoring and preparing a patient for surgery, wherein said monitoring and preparing comprises:
- obtaining a biological sample from the patient, wherein said biological sample includes at least one oligonucleotide occupying a locus corresponding to position 17 of SEQ ID. NO 1;
- detecting the identity of said at least one oligonucleotide occupying the locus corresponding to position 17 of SEQ ID. NO 1;
- determining whether said at least one oligonucleotide occupying the locus corresponding to position 17 of SEQ ID. NO 1 is an adenine or a cytosine;
- predicting and assessing the level of risk of the patient developing a MRSA infection, wherein an adenine occupying the locus corresponding to position 17 of SEQ ID. NO 1 indicates that the patient has a high risk of developing a MRSA infection and a cytosine occupying the locus corresponding to position 17 of SEQ ID. NO 1 indicates that the patient has a low risk of developing a MRSA infection;
- and
- wherein the predication and assessment indicates that the patient is at high risk for a MRSA infection, taking appropriate steps and care as one normally skilled in the art would take when operating on a person at high risk of developing a MRSA infection.
Dependencies are inferred from the claim text.